GlassScriptPhysician profile
Kenneth Edward Wong
NPI 1215935986
$12,073.65
in general payments reported to CMS, 2019-2025
33 companies · $1,793 in 2025
The $1,793 reported for 2025 was more than what 82% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,734 · 2020: $1,393 · 2021: $1,580 · 2022: $1,813 · 2023: $1,902 · 2024: $1,858 · 2025: $1,793.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,543 · Education: $10.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,542.98 |
| Education | $10.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,456.44 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,347.57 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $1,273.80 | 2019-2025 | |
| Pfizer INC. | $1,073.44 | 2019-2025 | |
| Amgen INC. | $965.49 | 2019-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $913.71 | 2019-2025 | Farxiga |
| Esperion Therapeutics, INC. | $604.64 | 2020-2025 | Nexletol |
| Merck Sharp & Dohme LLC | $580.49 | 2021-2025 | Verquvo, Capvaxive |
| E.R. Squibb & Sons, L.L.C. | $501.16 | 2019-2025 | Camzyos, Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $347.69 | 2019-2025 | Lifevest |
| Abbott Laboratories | $343.47 | 2023-2025 | Cardiomems, Amplatzer Amulet, Triclip |
| Bayer Healthcare Pharmaceuticals INC. | $333.74 | 2022-2024 | |
| Amarin Pharma, INC. | $289.08 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $257.70 | 2019-2024 | Livalo |
| Abiomed | $256.30 | 2020-2025 | Impella |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $180.04 | 2023-2025 | Wegovy, Ozempic |
| Cardiac Dimensions, INC. | $178.90 | 2024 | |
| Sanofi-Aventis U.S. LLC | $162.67 | 2019-2023 | |
| Medtronic, INC. | $162.03 | 2023 | Corevalve Evolut R |
| Kestra Medical Technology Services, INC. | $130.99 | 2022 | |
| Shockwave Medical, INC | $123.92 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Atricure, INC. | $106.10 | 2022-2025 | Atriclip Laa Exclusion System |
| Boston Scientific Corporation | $98.32 | 2020 | |
| Alnylam Pharmaceuticals INC. | $98.15 | 2024-2025 | Onpattro |
| Arbor Pharmaceuticals, INC. | $68.74 | 2019 | |
| Scpharmaceuticals INC. | $51.90 | 2024-2025 | |
| Lexicon Pharmaceuticals, INC. | $41.04 | 2023-2024 | Inpefa |
| Lilly USA, LLC | $32.68 | 2025 | Zepbound, Mounjaro |
| Gilead Sciences, INC. | $32.25 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $23.63 | 2024 | Arcalyst |
| Bard Peripheral Vascular, INC. | $17.75 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $14.33 | 2019 | |
| Itamar Medical INC | $5.49 | 2024 | Watchpatone |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Wong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.